Does Rallies show Form 4 insider transactions for NEO?

Yes. Rallies tracks NEO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NEO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NEO. It does not provide personalized investment advice.

NEO (NeoGenomics, Inc.) Stock Analysis - Insider Trades

NeoGenomics, Inc. (NEO) is a publicly traded Healthcare sector company. As of May 21, 2026, NEO trades at $8.85 with a market cap of $1.09B and a P/E ratio of 0.00. NEO moved +6.08% today. Year to date, NEO is -26.32%; over the trailing twelve months it is +11.39%. Its 52-week range spans $4.72 to $19.12. Analyst consensus is buy with an average price target of $14.94. Rallies surfaces NEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NEO stock inside the company?

Recent NEO insider activity includes Stone Warren sold 22.13K, Olivo Alicia C sold 20.92K, Olivo Alicia C sold 4.92K, Sherman Jeffrey Scott bought 20.00K, and Zook Anthony P. bought 17.90K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NEO Key Metrics

Key financial metrics for NEO
Metric	Value
Price	$8.85
Market Cap	$1.09B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$19.12
52-Week Low	$4.72
Volume	4.23K
Avg Volume	0
Revenue (TTM)	$727.33M
Net Income	$-108.03M
Gross Margin	43.21%

Recent NEO Insider Trades

Stone Warren sold 22.13K (~$276.68K) on Jan 20, 2026.
Olivo Alicia C sold 20.92K (~$250.99K) on Nov 25, 2025.
Olivo Alicia C sold 4.92K (~$49.18K) on Oct 16, 2025.
Sherman Jeffrey Scott bought 20.00K (~$112.32K) on Aug 6, 2025.
Zook Anthony P. bought 17.90K (~$99.95K) on Aug 6, 2025.

Latest NEO News

NeoGenomics Debuts RaDaR ST Assay for Residual Disease in Breast, Lung, Colorectal Tumors — Feb 25, 2026
NeoGenomics Down 22.8%, RSI 26.14 Signals Oversold, EPS Estimates Up 14.8% — Feb 20, 2026
NeoGenomics Reports 10% Revenue Growth to $727M Despite -$0.84 FY EPS — Feb 17, 2026
NeoGenomics Unveils PanTracer Pro with 500-Gene Profiling and 8-10 Day Turnaround — Feb 16, 2026
NeoGenomics Q3 Revenue Jumps 11.9% to $187.8M, Q4 Revenue Forecast at $188.3M — Feb 16, 2026

NEO Analyst Consensus

11 analysts cover NEO: 0 strong buy, 8 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.94.

Common questions about NEO

Who is trading NEO stock inside the company?: Recent NEO insider activity includes Stone Warren sold 22.13K, Olivo Alicia C sold 20.92K, Olivo Alicia C sold 4.92K, Sherman Jeffrey Scott bought 20.00K, and Zook Anthony P. bought 17.90K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NEO?: Yes. Rallies tracks NEO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NEO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NEO. It does not provide personalized investment advice.